500862-39-5

Basic information

• Product Name: 3-Bromo-5-chloro-1,3-benzenediamine
• Synonyms: 3-Bromo-5-chloro-1,3-benzenediamine;3-BroMo-5-chlorobenzene-1,2-diaMine;3-bromo-5-chloro-1,2-benzenediamine
• CAS NO: 500862-39-5
• Molecular Formula: C6H7BrClN2
• Molecular Weight: 222.49018
• Mol File: 500862-39-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 330.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.813±0.06 g/cm3(Predicted)
• PKA: 2.03±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-5-chloro-1,3-benzenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-chloro-1,3-benzenediamine(500862-39-5)
• EPA Substance Registry System: 3-Bromo-5-chloro-1,3-benzenediamine(500862-39-5)

Safety Data

• Hazardous Substances Data: 500862-39-5(Hazardous Substances Data)

Upstream product

• 827-25-8 2-bromo-4-chloro-6-nitrobenzenamine 
• 89-63-4 4-Chloro-2-nitroaniline 

Relevant articles and documents

Discovery and Structure–Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors

Energy and biomass production in cancer cells are largely supported by aerobic glycolysis in what is called the Warburg effect. The process is regulated by key enzymes, among which phosphofructokinase PFK-2 plays a significant role by producing fructose-2,6-biphosphate; the most potent activator of the glycolysis rate-limiting step performed by phosphofructokinase PFK-1. Herein, the synthesis, biological evaluation and structure–activity relationship of novel inhibitors of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which is the ubiquitous and hypoxia-induced isoform of PFK-2, are reported. X-ray crystallography and docking were instrumental in the design and optimisation of a series of N-aryl 6-aminoquinoxalines. The most potent representative, N-(4-methanesulfonylpyridin-3-yl)-8-(3-methyl-1-benzothiophen-5-yl)quinoxalin-6-amine, displayed an IC50 of 14 nm for the target and an IC50 of 0.49 μm for fructose-2,6-biphosphate production in human colon carcinoma HCT116 cells. This work provides a new entry in the field of PFKFB3 inhibitors with potential for development in oncology.

SUBSTITUTED QUINOXALINE DERIVATIVES

The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF

The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I): wherein R3, R4, R5, R6, R7, P, Q, V, W, X, Y, Z and a are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.